Belite Bio

Recent news

• Rating change
  Cantor Fitzgerald Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $270
  Market Newswire · 2026/8/14
• Rating change
  Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)
  TipRanks · 2026/8/31
• Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $234
  Market Newswire · 2026/9/9
• Rating change
  H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $214
  Market Newswire · 2026/9/3
• Rating change
  Maxim Group Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $200
  Market Newswire · 2026/8/16
• Rating change
  Morgan Stanley Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $206
  Market Newswire · 2026/8/17
• Rating change
  Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $220
  Market Newswire · 2026/8/14
• Rating change
  Cantor Fitzgerald Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $266
  Market Newswire · 2026/8/12
• Rating change
  Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)
  TipRanks · 2026/9/9
• CCORF Initiates Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $303
  Market Newswire · 2026/9/4
• Belite Bio(BLTE.US) Officer Sells US$12.8 Million in Common Stock
  Market Newswire · 2026/9/10
• Rating change
  Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)
  TipRanks · 2026/8/16
• Rating change
  H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $245
  Market Newswire · 2026/9/9
• Rating change
  Mizuho Securities Remains a Buy on Belite Bio, Inc. ADR (BLTE)
  TipRanks · 2026/8/14
• Rating change
  Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE)
  TipRanks · 2026/8/15
• Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $220
  Market Newswire · 2026/9/6
• Rating change
  A Quick Look at Today's Ratings for Belite Bio(BLTE.US), With a Forecast Between $201 to $270
  Market Newswire · 2026/8/15
• Rating change
  BofA Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $200
  Market Newswire · 2026/9/3
• Belite Bio(BLTE.US) Officer Sells US$19.08 Million in Common Stock
  Market Newswire · 2026/9/10
• Rating change
  H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $245
  Market Newswire · 2026/9/8

Headlines are aggregated automatically and are not independently verified or edited by our team.